These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 21522004)

  • 1. Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies.
    Rockstroh JK; Teppler H; Zhao J; Sklar P; Miller MD; Harvey CM; Strohmaier KM; Leavitt RY; Nguyen BY
    AIDS; 2011 Jul; 25(11):1365-9. PubMed ID: 21522004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials.
    Eron JJ; Cooper DA; Steigbigel RT; Clotet B; Gatell JM; Kumar PN; Rockstroh JK; Schechter M; Markowitz M; Yeni P; Loutfy MR; Lazzarin A; Lennox JL; Strohmaier KM; Wan H; Barnard RJ; Nguyen BY; Teppler H;
    Lancet Infect Dis; 2013 Jul; 13(7):587-96. PubMed ID: 23664333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection.
    Rockstroh J; Teppler H; Zhao J; Sklar P; Harvey C; Strohmaier K; Leavitt R; Nguyen BY
    HIV Med; 2012 Feb; 13(2):127-31. PubMed ID: 21599819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.
    Rockstroh JK; Lennox JL; Dejesus E; Saag MS; Lazzarin A; Wan H; Walker ML; Xu X; Zhao J; Teppler H; Dinubile MJ; Rodgers AJ; Nguyen BY; Leavitt R; Sklar P;
    Clin Infect Dis; 2011 Oct; 53(8):807-16. PubMed ID: 21921224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.
    Rockstroh JK; DeJesus E; Lennox JL; Yazdanpanah Y; Saag MS; Wan H; Rodgers AJ; Walker ML; Miller M; DiNubile MJ; Nguyen BY; Teppler H; Leavitt R; Sklar P;
    J Acquir Immune Defic Syndr; 2013 May; 63(1):77-85. PubMed ID: 23412015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
    Cooper DA; Steigbigel RT; Gatell JM; Rockstroh JK; Katlama C; Yeni P; Lazzarin A; Clotet B; Kumar PN; Eron JE; Schechter M; Markowitz M; Loutfy MR; Lennox JL; Zhao J; Chen J; Ryan DM; Rhodes RR; Killar JA; Gilde LR; Strohmaier KM; Meibohm AR; Miller MD; Hazuda DJ; Nessly ML; DiNubile MJ; Isaacs RD; Teppler H; Nguyen BY;
    N Engl J Med; 2008 Jul; 359(4):355-65. PubMed ID: 18650513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study.
    Gatell JM; Katlama C; Grinsztejn B; Eron JJ; Lazzarin A; Vittecoq D; Gonzalez CJ; Danovich RM; Wan H; Zhao J; Meibohm AR; Strohmaier KM; Harvey CM; Isaacs RD; Nguyen BY;
    J Acquir Immune Defic Syndr; 2010 Apr; 53(4):456-63. PubMed ID: 20306554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.
    Raffi F; Rachlis A; Stellbrink HJ; Hardy WD; Torti C; Orkin C; Bloch M; Podzamczer D; Pokrovsky V; Pulido F; Almond S; Margolis D; Brennan C; Min S;
    Lancet; 2013 Mar; 381(9868):735-43. PubMed ID: 23306000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.
    Steigbigel RT; Cooper DA; Teppler H; Eron JJ; Gatell JM; Kumar PN; Rockstroh JK; Schechter M; Katlama C; Markowitz M; Yeni P; Loutfy MR; Lazzarin A; Lennox JL; Clotet B; Zhao J; Wan H; Rhodes RR; Strohmaier KM; Barnard RJ; Isaacs RD; Nguyen BY;
    Clin Infect Dis; 2010 Feb; 50(4):605-12. PubMed ID: 20085491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
    Raffi F; Jaeger H; Quiros-Roldan E; Albrecht H; Belonosova E; Gatell JM; Baril JG; Domingo P; Brennan C; Almond S; Min S;
    Lancet Infect Dis; 2013 Nov; 13(11):927-35. PubMed ID: 24074642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004).
    Gotuzzo E; Markowitz M; Ratanasuwan W; Smith G; Prada G; Morales-Ramirez JO; Strohmaier KM; Lu C; Bhanja S; Nguyen BY; Teppler H;
    J Acquir Immune Defic Syndr; 2012 Sep; 61(1):73-7. PubMed ID: 22743596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium.
    Nguyen BY; Isaacs RD; Teppler H; Leavitt RY; Sklar P; Iwamoto M; Wenning LA; Miller MD; Chen J; Kemp R; Xu W; Fromtling RA; Vacca JP; Young SD; Rowley M; Lower MW; Gottesdiener KM; Hazuda DJ
    Ann N Y Acad Sci; 2011 Mar; 1222():83-9. PubMed ID: 21434946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses.
    Lennox JL; Dejesus E; Berger DS; Lazzarin A; Pollard RB; Ramalho Madruga JV; Zhao J; Wan H; Gilbert CL; Teppler H; Rodgers AJ; Barnard RJ; Miller MD; Dinubile MJ; Nguyen BY; Leavitt R; Sklar P;
    J Acquir Immune Defic Syndr; 2010 Sep; 55(1):39-48. PubMed ID: 20404738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.
    Markowitz M; Nguyen BY; Gotuzzo E; Mendo F; Ratanasuwan W; Kovacs C; Prada G; Morales-Ramirez JO; Crumpacker CS; Isaacs RD; Gilde LR; Wan H; Miller MD; Wenning LA; Teppler H;
    J Acquir Immune Defic Syndr; 2007 Oct; 46(2):125-33. PubMed ID: 17721395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.
    Grinsztejn B; Nguyen BY; Katlama C; Gatell JM; Lazzarin A; Vittecoq D; Gonzalez CJ; Chen J; Harvey CM; Isaacs RD;
    Lancet; 2007 Apr; 369(9569):1261-1269. PubMed ID: 17434401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raltegravir: in treatment-naive patients with HIV-1 infection.
    Croxtall JD; Scott LJ
    Drugs; 2010 Mar; 70(5):631-42. PubMed ID: 20329808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety from the raltegravir clinical development program.
    Teppler H; Brown DD; Leavitt RY; Sklar P; Wan H; Xu X; Lievano F; Lehman HP; Mast TC; Nguyen BY
    Curr HIV Res; 2011 Jan; 9(1):40-53. PubMed ID: 21198432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raltegravir in treatment naive patients.
    Cossarini F; Castagna A; Lazzarin A
    Eur J Med Res; 2009 Nov; 14 Suppl 3(Suppl 3):22-9. PubMed ID: 19959413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients.
    Skiest DJ; Cohen C; Mounzer K; Haigney Z; Barker D; Gottlieb M; Bellman PC; Dejesus E; Khanlou H; Ruane PJ; Hsiao CB; Abriola K; Rashbaum B; Bellos N; Ward D; Colson A; Santiago F; Habel A; Garb J
    HIV Clin Trials; 2011; 12(3):131-40. PubMed ID: 21684853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.
    Lennox JL; DeJesus E; Lazzarin A; Pollard RB; Madruga JV; Berger DS; Zhao J; Xu X; Williams-Diaz A; Rodgers AJ; Barnard RJ; Miller MD; DiNubile MJ; Nguyen BY; Leavitt R; Sklar P;
    Lancet; 2009 Sep; 374(9692):796-806. PubMed ID: 19647866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.